Introduction
Many nucleoside analogues used in hematological malignancies such as cytosine arabinoside (Ara-C), 1 cladribine (CdA), fludarabine, gemcitabine and 9-␤-d-arabinofuranosylguanine (Ara-G) are phosphorylated by the enzyme deoxycytidine kinase (dCK) to its monophosphate form in order to exert a cytotoxic effect on leukemic cells. Mitochondria require deoxynucleoside triphosphates for incorporation into its DNA. The mitochondrial enzyme deoxyguanosine kinase (dGK) phosphorylates several important nucleoside analogues. 1 Both purine and pyrimidine analogues can be dephosphorylated by members of the 5′-nucleotidase (5′-NT) enzyme family and by non-specific phosphatases. The low-K m 5′-NT dephosphorylates pyrimidine monophosphates and the high-K m 5′-NT is specific for purine ribonucleotides. 2 Ara-C is used in the treatment of childhood acute lymphoblastic leukemia (ALL). The response rate in patients treated according to the regimens is more than 90%, but 25% of them relapse indicating that there is a clinical resistance, either present at diagnosis or evolving during treatment. CdA has been shown to be effective against various diseases, especially hairy cell leukemia with 95% response. In pediatrics, CdA has been used for acute leukemias and has been particularly effective in acute myeloid leukemia (AML). 3 Clinical data have so far indicated that dCK is important for the effect of nucleoside analogues and it has been shown that resistance can be related to dCK deficiency, [4] [5] [6] although there have been conflicting results, some studies showing patients resistant towards analogues with normal levels of dCK. In vitro studies demonstrate that cell lines selected for resistance to nucleoside analogues often have a lack of dCK activity. [7] [8] [9] [10] Techniques which have often been employed for dCK analysis are enzyme activity measurements in crude extracts, immunoblotting, Northern blot and semi-quantitative PCR. Antibodies for dCK, dGK and 5'-NT are not commercially available. The disadvantage with enzyme activity measurements for dCK (using deoxycytidine as substrate) is that dCK has overlapping substrate specificity with the mitochondrial enzyme thymidine kinase 2. DCK also has overlapping substrate specificity with dGK, although dGK can only phosphorylate purine nucleosides. 11 The development of RT-PCR has allowed more accurate quantitative determination, 12 but the method requires post-PCR handling, also the quantification of the intensity of bands is done manually. In this study, we established a quantitative and highly reproducible realtime quantitative PCR (RQ-PCR) method for the measurement of the mRNA levels of dCK, dGK and 5′-NT. This method is based on the use of the 5′-nuclease activity of Taq polymerase to cleave a non-extendable fluorogenic hybridization probe during the extension phase of PCR. 12, 13 Thus, the aim of the present study was to develop a RQ-PCR to measure dCK, dGK and 5′-NT mRNA expression. We compared the RQ-PCR method with enzyme activity measurements and semi-quantitative PCR in a T-lymphoblastic MOLT-4 cell line resistant to the cytotoxic effect of nucleoside analogues. The clinical applicability of the method has also been investigated in samples from pediatric patients with ALL and AML.
Materials and methods

Patients and isolation of leukemic cells
The study included 32 childhood ALL aged from 1 to 15 years and three childhood AML patients, aged from 12 to 14 years. The ALL and AML patients included 14 (40%) females and 21 (60%) males. Of the 32 ALL cases, four children were classified as T cell, 26 as B-precursor, one as mature B cell and one child had unknown phenotype. Cytogenetic analyses were performed in all cases and 10 had a diploid karyotype, one had a t(9;22), three children had t(12;21), eight cases were hyperdiploid (у51 chromosomes) and 10 had other abnormalities. Negative clinical events were defined as induction failure, relapse or death during remission. Samples were taken at diagnosis except for four patients, where these patients' samples were taken after the start of treatment. The study was approved by the local ethics committee at Karolinska Hospital. Bone marrow samples were obtained by aspiration, put on ice and immediately transported to the laboratory. Mononuclear cells were isolated by density gradient centrifugation with Lymphoprep (Nycomed, Oslo, Norway). Cells were kept in liquid nitrogen prior to RNA extraction. For children with ALL, the blast fraction at diagnosis was Ͼ85% and for the three AML patients it was 95%, 72% and 31%, respectively.
Chemicals
␣,␤-methylene adenosine 5′-diphosphate, inosine, imidazole hydrochloride and hypoxanthine, inosine 5′-monophosphate, ␤-glycerophosphate, adenosine 5′-triphosphate and ethylene glycol-bis(␤-aminoethyl ether) n,n,n′,n′-tetraacetic acid (EGTA), ampicillin, 5-bromo-4-chloro-3-indolyl ␤-d-galactopyranoside (X-gal) and isopropylthio-␤-d-galactoside (IPTG) were provided by Sigma (St Louis, MO, USA). 5-3 H-dCyd (16.7 Ci/mmol), H-CdA (4 Ci/mmol), 8-3 H-9-␤-d-arabinofuranosylguanine (Ara-G) (2 Ci/mmol) and 8-14 C-inosine 5′-monophosphate, diammonium salt (55 mCi/mmol) were purchased from Moravek Biochemicals (Brea, CA, USA). RPMI 1640 medium, heat-inactivated fetal calf serum, l-glutamine and penicillin-streptomycin were from Gibco (Life Technologies, Paisley, UK). All reagents for PCR reactions and the fluorescent probes were purchased from Perkin Elmer (Foster City, CA, USA). The primers were made by DNA Technology A/S (Aarhus, Denmark) and CyberGene (Stockholm, Sweden).
Cell lines and culture conditions
The MOLT-4 human T cell line was obtained from American Type Culture Collection (Rockville, MD). Cells were maintained in a humidified, 5% CO 2 incubator at 37°C in RPMI 1640 medium supplemented with fetal calf serum (10%) and l-glutamine (2 mm), and split twice weekly. The MOLT-4 was selected for resistance to Ara-G. The resistant cells were designated as MOLT-4/M. The number of cells were determined by a Coulter Multisizer (Coulter Electronics, Luton, UK).
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RNA extraction and cDNA synthesis
Cells were collected by centrifugation and total cellular RNA in the cell lines was extracted using midi-kit (Qiagen, Stockholm, Sweden). For extraction of cellular RNA from patients the ULTRASPEC-II RNA kit was used (Biotecx, Houston, TX, USA). The RNA purity and yield were determined spectrophotometrically with Gene Quant RNA/DNA Calculator (Pharmacia Biotech, Uppsala, Sweden). For the synthesis of cDNA, a total volume of 100 l reaction mixture including 5 g total RNA was used. The reverse transcription was performed according to the manufacturer's instruction using a RNA-PCR kit (Perkin Elmer) with random hexamers as primers.
Semi-quantitative PCR
The primers used are shown in Table 1 . To amplify the cDNA, a reaction mixture containing 1 × PCR buffer, 2 mm MgCl 2 , 0.8 mm each of dATP, dCTP, dGTP and dTTP, 0.1 m of primers and 0.625 U of Taq DNA polymerase, were mixed in a total volume of 25 l. The internal control ␤2-microglobulin was used.
14 The linearity was tested by adding different concentrations of the template and running different numbers of cycles during the reaction. To test the linearity, a range of dilutions of the template was used in each experiment. For dCK, dGK and 5′-NT, 0.025-0.075 g reversed transcribed cDNA was used and for ␤2-microglobulin, 0.013-0.5 g cDNA was used. For dCK and dGK the reaction consisted of 34 cycles and for 5′-NT of 32 cycles (94°C for 30 s, 58°C for 30 s and 72°C for 30 s) in a DNA thermal cycler (Perkin-Elmer 9600). The reaction for ␤2-microglobulin consisted of 25 cycles (94°C for 30 s, 60°C for 30 s and 72°C for 30 s). ␤2-microglobulin cDNA was amplified as a reference gene to avoid differences in mRNA amount or reverse transcription efficiencies. The amplification products were electrophoresed in 1.5% agarose gel and photographed as ethidium bromide fluorescent bands. The PCR products were sized by a ⌽X174 RF DNA/HaeIII fragment (Life Technologies, Stockholm, Sweden). The PCR procedure was performed at least three times for each sample.
Cloning of cDNA standards and dGK cDNA
Clones containing ␤2-microglobulin, dCK, dGK and 5′-NT cDNA were constructed by ligation of 0.5 g PCR-amplified cDNA in the modified pBluescript vector pMON. 15 Primers and amplification conditions were the same as described above. The PCR products were purified using the JET QUICK Purification Spin Kit/50 (Saveen, Malmö , Sweden) and ligated using Ready-To-Go T4 DNA Ligase (Pharmacia Biotech, Uppsala, Sweden) into the pMON vector. The ligated material was transformed into E. coli XL-1 (Stratagene, La Jolla, CA, USA) cells by electroporation. Bacteria carrying recombinant plasmids were screened for white colonies on a LB agar plate with ampicillin (50 g/ml), X-gal and IPTG. Recombinant plasmids containing the inserts were identified by PCR amplification of single colonies followed by electrophoresis of the PCR products and nucleotide sequence analysis using PRISM Ready Reaction DyeDeoxy Terminator sequencing kit (PerkinElmer, Norwalk, CT, USA) of the PCR products. Plasmids with the appropriate inserts were purified using Wizard DNA Purification Midiprep (Promega, Madison, WI, USA) and used as standards in RQ-PCR. 
Real-time quantitative PCR (RQ-PCR)
RQ-PCR was performed as earlier described by Gibson et al. 16 The method has been previously described for dCK and 5′-NT, 10 but has been modified here to more suitable primers and probes. The reverse primer for dCK was changed and placed over an exon-border. The 5′-NT primers and probe were changed in order to fit into the area of the cDNA standard, which was used here to do the quantification. Previous primers were compared with current primes showing no difference in the quantitation of dCK and 5′-NT. The primer design software Primer Express (Perkin-Elmer Applied Biosystems, Foster City, CA, USA) was used to design primers and the Taqman probes for ␤2-microglobulin, dCK, dGK and 5′-NT. VIC was chosen as reporter dye for ␤2-microglobulin, FAM (6-carboxy-fluorescein) for dCK and 5′-NT and TET (tetrachloro-6-carboxy-fluorescein) for dGK. The oligonucleotides are shown in Table 1 . Reactions were performed and data collected by the ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems). ␤2-microglobulin is used as reference gene. Results are expressed as the ratio of dCK, dGK or 5′-NT and ␤2-microglobulin. 
Measurement of dCK and dGK enzyme activity
The enzyme activities were determined in crude extracts with 3 H-dCyd, 3 H-CdA and 3 H-Ara-G as substrates as described previously. 17 Briefly, cells were extracted and used as a source of protein for the enzyme assays. To measure the dGK activity, CdA or Ara-G was used as substrate and excess of deoxycytidine was added. For the substrate, the concentration was consistently chosen to be 10 times higher than the K m value for the kinase phosphorylating the substrate. The assays were initiated by addition of 2-3 g protein to a reaction mixture containing 50 mm TRIS-HCl (pH 7.6), 5 mm MgCl 2 , 5 mm ATP, 4 mm DTT, 10 mm NaF and substrates. The reaction mixture was incubated for 20 min and 10 l aliquots were spotted on WATMAN DE-81 filter discs. The discs were washed as described, 17 eluted by 100 l of 0.4 m PCA and the radioactivity was estimated in a liquid scintillation counter (RackBeta; LKB Wallace, Turku, Finland) after addition of 3 ml Ecoscint scintillation fluid (National Diagnostics, Atlanta, GA, USA). The conditions which maintained linear reaction rate were determined in preliminary experiments. The specific activity of the enzyme was expressed in pmoles of phosphorylated substrate per mg protein per minute.
5′-NT enzyme assay
The activity of 5′-NT was measured in crude cell extracts using a radiochemical assay previously described by Spychala et al. 8 The reaction mixture had a total volume of 25 l and contained of 50 mm imidazole, pH 7.5, 50 mm NaCl, 10 mm MgCl 2 , 0.5 g/l BSA, 0.2 mm ␣,␤-methylene adenosine diphosphate, which inhibits the activity of the membrane-bound 5′-ecto-NT, 5 mm ␤-glycerophosphate, 100 m EGTA and 50 to 200 m IMP and [ 14 C]-IMP as substrate. To measure high-K m 5′-NT, 3 mm ATP was added to activate the enzyme. The reaction was assayed for 30 min at 37°C and was stopped by adding formic acid, then briefly centrifuged. Subsequently 10 l of the reaction sample was added to a thin-layer chromatography plate (PEI-cellulose F, TLC plastic sheets), which was developed in 1-butanol:H 2 O:methanol:NH 4 (60:20:20:1 vol/vol). Spots comigrating with the inosine and hypoxanthine markers and which were visible in UV-light were cut out and put into scintillation vials to which 3 ml of Ultima Gold (Packard) was added. The radioactivity was counted in a liquid scintillation counter (RackBeta; LKB Wallac), where the activity was expressed in picomoles per minute per milligram of protein.
Western blot
The levels of dCK and dGK were determined by the Western blot method using a peptide anti-dCK antibody as described previously, 19 and an affinity-purified antibody was used for dGK. 20 Approximately 40 g of crude cell extract was analyzed and the protein bands were detected by the ECL method, as earlier described. 10 
Statistical analyses
Statistics were calculated using StatView software (Abacus Concepts, Berkeley, CA, USA). Correlation between dCK and dGK expressions for patient samples was based on the nonparametric Spearman rank correlation test. A P value of р0.05 was considered as statistically significant.
Results
Construction of primers and probes for RQ-PCR
From the available dCK (GI:4503268) and 5'-NT (GI:633070) cDNA sequences we constructed specific primers and fluorogenic probes (primer design software Primer Express) for the respective gene (Table 1) . Different isoforms of dGK were investigated, 21 and appropriate primers for conventional PCR and for RQ-PCR for dGK was constructed.
Determination of the linear range of the amplification curve
Determination of the mRNA expression of dCK, dGK and 5′-NT was performed by calculating the unknown sample concentration relative to a standard. A serial dilution of the dCK (Figure 1a, b) , dGK and 5′-NT (data not shown) standards gives a plot of total fluorescence (⌬Rn) vs threshold cycle (C T ). Standard curves were derived from the amplification plot resulting in threshold cycle (C T ) plotted against the copy number. The dynamic range was wide with dilutions from 10 1 to 10 5 copies for ␤2-microglobulin, dCK and dGK and 10 2 to 10 5 copies for 5′-NT (data not shown). The slopes for the standard curves for ␤2-microglobuline, dCK, dGK and 5′-NT plasmid cDNA were −3.41, −3.42, −3.65 and −4.28, for dCK, dGK, 5'-NT and the internal standard and the intercept was 38.54, 36.09, 40.11 and 40.70, respectively. The correlation
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Figure 1
(a) Amplification plot for dCK with five different dilutions in duplicates ranging from 10 1 to 10 5 input copies of the plasmid cDNA standards. The x axis denotes the C T , cycle number and the y axis denotes the ⌬Rn which is the fluorescence intensity over the background. (b) The standard curve for dCK cDNA standards was derived from the amplification plot. The x-axis shows the input number of gene copies and the y axis shows the threshold cycle for the detection of significant florescence. The slope for dCK was −3.42 and the correlation coefficient was 0.999. The slopes for ␤2-microglobulin, dGK and 5′-NT were −3.41, −3.65 and −4.28, respectively, and the correlation coefficients were 0.999, 0.996 and 0.996, respectively (data not shown).
coefficients for the corresponding genes were 0.999, 0.999, 0.996 and 0.996, respectively. The between-run coefficients of variation of the ratio of the copy numbers for dCK, 5′-NT and the reference gene were less than 11% and the coefficient of variation for dGK was less than 22% (Table 2) . 
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Comparison between the different detection methods, RQ-PCR, semi-quantitative PCR, Western blot and enzyme activity measurements in cell lines
Using the RQ-PCR, the amount of dCK, dGK and 5′-NT mRNA expression in MOLT-4 wild-type and the Ara-G-resistant subline (MOLT-4/M) was determined ( Table 2) . Ara-G-resistant cells will be described elsewhere in an ongoing study. The MOLT-4/M had decreased mRNA expression of dCK (53% for MOLT-4/M) and of 5′-NT (50% for MOLT-4/M) as compared to the wild-type ( Table 2 ). The mRNA expression of dGK was only somewhat reduced in the resistant cell line as compared to the wild-type. The RQ-PCR was compared to semi-quantitative PCR. Gel electrophoretic analysis of PCR products for dCK, dGK, 5′-NT and the reference gene ␤2-microglobulin for the cell lines was performed and the optical density was measured. In case of dCK and 5′-NT the MOLT-4/M showed decreased intensity of the bands as compared to the wild-type cells. The reduction of the intensity of the dCK band relative to ␤2-microglobulin was approximately 50% for MOLT-4/M as compared to the wild-type (Figure 2 ). The optical density of the 5'-NT band for the MOLT4/M cell line was reduced approximately 40%, compared to the wild-type and the intensity of the dGK bands relative to ␤2-microglobulin was approximately 80-90% for the mutant as compared to the wild-type (Figure 2) . Table 2 shows in vitro enzyme activity measurements. The enzyme measurements were performed in order to elucidate if the mRNA levels of dCK, dGK and 5′-NT correlate with the activity of the enzyme. The dCK activity was measured as the conversion of CdA to its monophosphate form, representing the catalytic activity of the enzyme. 22 The MOLT-4 resistant cells showed reduced dCK activity, it had 42% dCK activity as compared to the wild-type. The dGK activity was measured using CdA as substrate and excess of deoxycytidine was added. The dGK activity was reduced to 26% for the MOLT-4/M resistant cells as compared to the wild-type. The activity of high K m 5′-NT of MOLT-4/M mutants as measured by IMP conversion was reduced to 48%, as compared to the wildtype ( Table 2 ). As analyzed with Western blot, the protein lev-
Figure 2
Semi-quantitative PCR of ␤2-microglobulin, dCK, dGK and 5'-NT in cell lines with different sensitivities to nucleoside analogues, MOLT-4/M and the wild type. Electrophoretic separation on a 1.5% agarose gel with ethidium bromide staining is shown. The sizes of the amplified cDNA fragments are 280 bp for ␤2-microglobulin, 783 bp for dCK, 414 bp for dGK and 1059 bp for 5′-NT. The optical density of the bands was measured. els were obtained and the optical density was measured. The intensity of the dCK protein band for MOLT-4/M was 33% as compared to MOLT-4/wt, using an antibody against dGK showed that the intensity of the dGK band for MOLT-4/M was 66% as compared to MOLT-4/wt.
RQ-PCR analysis of dCK and 5′-NT in childhood ALL and AML
The dCK, dGK and 5′-NT mRNA expression was measured in 35 bone marrow samples with leukemic cells from pediatric patients with ALL and AML by RQ-PCR. There was a large variability of mRNA expression of the genes between the samples ( Table 3 ). The median of dCK mRNA expression in ALL (n = 32) was 0.46 and 1.45 in AML (n = 3) ( Table 3 ). The median of 5′-NT mRNA expression was 0.13 for ALL and 0.02 for AML patients. The mRNA expression for dGK relative to the reference gene showed an interindividual variability from non-detectable to 0.06. The dGK mRNA expression was much lower than the dCK mRNA expression and could not be detected for the AML pediatric patients, the median of dGK mRNA expression for the ALL patients was 0.01. The dCK/5'-NT mRNA ratio was 26 for AML and 3 for ALL. There was no significant correlation between dCK and dGK mRNA expression in patient samples (Rho-value = −0.30, P = 0.08). Negative clinical events that occurred among these patients were two induction failures, four relapses and one death during remission (Table 3) . These patients had relatively high levels of dCK mRNA expression and varied levels of 5′-NT and dGK mRNA expression. The prognostic value could not be analyzed due to few cases of negative events.
Discussion
The mechanisms of resistance to nucleoside analogues remains to be clarified in patient samples and tools are needed to study this in more detail. In the current study we have evaluated the RQ-PCR for quantitating the mRNA levels and we compared the method to other methods: semi-quantitative PCR, Western blot analysis and enzyme activity measurements in cell lines resistant to nucleoside analogues.
In the present study, we found that the resistant cells had reduced levels of mRNA expression and enzyme activity for dCK and 5'-NT, as determined using RQ-PCR, semi-quantitative PCR and enzyme activity measurements. Western blot analysis also showed reduced dCK protein levels for the resistant cell line as compared to the parental cell line. Others have shown that the levels of dCK mRNA as measured by quantitative competitive PCR were related to the dCK activity, particularly in cell lines but also in ALL and AML leukemic cells. 23 We presented results in an earlier study showing that the mRNA levels and enzyme activity were similar for dCK and 5′-NT in a myeloid cell line resistant to CdA and fludarabine. 10 Using a direct immunoassay for dCK Kawasaki et al 24 showed that CdA responders had significantly higher dCK levels and lower 5′-NT levels than non-responders in samples from patients with hairy cell leukemia or chronic lymphocytic leukemia. A recent study in the myeloid cell line HL60 showed that altered mRNA expression and specific activity of 5′-NT can induce resistance to CdA, 2 altered levels of 5'-NT is also an adverse prognostic factor in AML patients 25 and in ALL patients. 26 However, overexpression of high K m 5′-NT in human 293 cells did not introduce resistance to deoxyadenosine or deoxyguanosine. 27 Recently two new 5′-NTs have been 391 Table 3 Levels of mRNA expression of dCK, dGK, 5′-NT and the ratio of dCK and 5′-NT in pedriatic patients with leukemia reported of, one cytosolic 5′(3′)-deoxyribonucleotidase 28 and a mitochondrial 5′-nucleotidase, dNT-2. 29 Although the relative involvement of these nucleotidases in the catabolism of nucleoside analogues and their clinical relevance as prognostic factors remain to be studied.
RQ-PCR and semi-quantitative PCR showed similar results for dGK. Western blot showed approximately a 30% reduction of the dGK protein for MOLT-4/M, while the enzyme measurements showed a 70% lower dGK activity in the resistant cell line ( Figure 2 , Table 2 ). Thus, there appear to be post-translational processes of importance for the regulation of dGK enzyme levels but this need to be further studied.
To demonstrate the clinical applicability of the method, we quantified dCK, dGK and 5′-NT mRNA expressions by RQ-PCR in 35 pediatric ALL and AML patients. The dCK and 5′-NT mRNA expression varied 39-fold and eight-fold, respectively, and the dGK mRNA expression varied from non-detectable to 0.06 (Table 3 ). The levels of dGK mRNA expression were much lower in both the MOLT-4 cell line and in the Leukemia pediatric patient samples as compared to the dCK mRNA expression. Stammler et al 30 showed that patients with initial ALL experienced a relapse more frequently if dCK expression was low or absent as measured by semi-quantitative PCR. It has been suggested that 5′-NT is of prognostic value for ALL. 26 In this limited patient group we could not draw any conclusions of these genes serving as prognostic factors, a larger group of patients need to be studied in order to do that.
There was a three-fold difference in the median of dCK mRNA expression between ALL and AML pediatric patients (Table 3) , and a 10-fold difference in median of the ratio of dCK and 5′-NT between ALL and AML patient samples. The dGK mRNA expression was non-detectable in AML patient samples and the median for ALL was 0.01. Based on higher affinity of CdA and its newer analogue 2-chloro-2′-arabinofluoro-2′-deoxyadenosine for dCK and the mitochondrial enzyme dGK, it is possible that the newer analogues may be more effective than Ara-C in certain therapeutic combination strategies. 31 Compared to the semi-quantitative PCR, the RQ-PCR method is superior in many ways. The PCR product is determined in real time and not only at an end point, avoiding the danger of estimating the product at the plateau stage. Furthermore, the use of three sequence-specific oligonucleotides compared to two in conventional PCR settings adds specificity. Moreover, compared to enzyme activity measurements, the RQ-PCR is much more specific but the problem of posttranscriptional regulation cannot be addressed by this method.
The present method is a valuable tool in the determination of dCK, dGK and 5′-NT mRNA gene expressions in cell lines and in clinical samples. The aim to find genetic markers serving as prognostic factors to optimize the treatment of hematological malignancies with nucleoside analogues remains to be further investigated with the method described.
